Today: 19 May 2026
Browse Category

NYSE:CVS 14 December 2025 - 28 January 2026

Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

The Dow Jones hovered near 49,000 Wednesday morning, dipping 3.56 points to 48,999.85 as UnitedHealth’s sharp fall continued to weigh on the index. The S&P 500 briefly topped 7,000, boosted by chip stocks after upbeat results from ASML and SK Hynix. The Federal Reserve’s policy decision is due at 2 p.m. EST. Meta, Microsoft, Tesla, and IBM report earnings after the bell.
28 January 2026
···········
Dow Jones today: Dow futures inch up as Fed decision and Big Tech earnings loom

Dow Jones today: Dow futures inch up as Fed decision and Big Tech earnings loom

Dow futures rose about 30 points ahead of the Fed’s policy decision, with S&P 500 and Nasdaq 100 futures also up. Health insurers slumped after U.S. officials proposed a 0.09% Medicare Advantage payment hike, far below expectations. The Dow fell 409 points Tuesday, dragged by UnitedHealth, Humana, and CVS losses, while the S&P 500 and Nasdaq hit records on tech gains. Microsoft and Meta will report earnings Wednesday.
28 January 2026
·····
CVS stock price dives 14% after CMS Medicare Advantage rate proposal; what investors watch next

CVS stock price dives 14% after CMS Medicare Advantage rate proposal; what investors watch next

CVS Health shares dropped about 14% to $72 in after-hours trading Tuesday after a proposed 2027 Medicare Advantage payment update signaled minimal rate increases. The Centers for Medicare & Medicaid Services projected a 0.09% average hike, sparking warnings from insurers about possible benefit cuts. UnitedHealth and Humana shares also fell sharply. CVS reports earnings Feb. 10; CMS’s final decision is due in April.
28 January 2026
·
UnitedHealth Group stock price tumbles: UNH slides nearly 20% after outlook, Medicare Advantage rates in focus

UnitedHealth Group stock price tumbles: UNH slides nearly 20% after outlook, Medicare Advantage rates in focus

UnitedHealth Group shares fell 19.5% to $282.90 in after-hours trading Tuesday after a weak Medicare Advantage rate proposal from the Trump administration. The company expects to lose up to 1.4 million Medicare Advantage members in 2026 and forecasts a drop in Medicaid membership. CVS and Humana shares also plunged. The government’s final Medicare Advantage rate decision is due April 6.
27 January 2026
···
UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth shares fell 18.4% to $286.96 Tuesday after a U.S. proposal signaled Medicare Advantage payments would rise just 0.09% in 2027. The company warned of its first revenue drop since 1989 despite maintaining its 2026 profit outlook. CVS Health and Humana also posted sharp declines. CMS will accept comments on the proposed rates through Feb. 25.
27 January 2026
···
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

The Dow Jones fell 445 points, or 0.9%, to 48,966 in early trading, dragged down by a 20% plunge in UnitedHealth after weak Medicare payment proposals and a downbeat 2026 forecast. U.S. consumer confidence dropped to its lowest since 2014. The S&P 500 and Nasdaq rose, while Humana and CVS also tumbled. Traders watched for earnings and the Fed meeting starting Tuesday.
27 January 2026
···
CVS stock slides before the bell as Medicare Advantage rate shock hits insurers

CVS stock slides before the bell as Medicare Advantage rate shock hits insurers

CVS Health shares fell about 9% in premarket trading after CMS announced a 0.09% net average payment increase for 2027 Medicare Advantage plans, far below investor expectations. The agency set a Feb. 25 deadline for comments and will finalize rates by April 6. UnitedHealth and Humana also dropped in after-hours trading. Insurers face pressure as Medicare Advantage remains a key profit source.
27 January 2026
·
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
·····
UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth shares fell 1.3% to $334.40 Friday, weighing on the Dow as managed-care stocks slid after Trump’s new healthcare proposal. The plan, which would replace insurance subsidies with direct payments to consumers, left policy details unclear and insurers under pressure. UnitedHealth will report 2025 earnings and its 2026 outlook on Jan. 27. Investors are watching for updates on government-plan costs and future guidance.
16 January 2026
······
UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

U.S. House committees summoned UnitedHealth and four other insurers to testify on coverage affordability Jan. 22. UnitedHealth shares rose 1.5% to $346.85 after Wolfe Research raised its price target to $400. The company reports 2025 earnings and 2026 guidance Jan. 27. Senators also accused UnitedHealth of withholding documents in a nursing home care probe.
9 January 2026
·····
UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth shares rose 1.3% to $346.11 after U.S. House lawmakers called major health insurer CEOs to testify on coverage affordability January 22. Senators Wyden and Warren accused UnitedHealth of withholding documents in a nursing-home probe, setting a January 28 deadline. TPG is in advanced talks to buy UnitedHealth’s Optum UK unit for up to £1.4 billion, Sky News reported.
8 January 2026
····
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth shares fell over 2% to $340.44 Wednesday morning, erasing part of Tuesday’s gain. The drop followed analyst moves, with Bernstein raising its target to $444 and Evercore ISI starting coverage at $400. Investors await UnitedHealth’s Jan. 27 results and Medicare Advantage rate updates. Humana and Cigna also declined.
7 January 2026
·······
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth shares rose 0.8% to $338.94 in late-morning trading Monday after Barclays raised its price target to $391 and reiterated an Overweight rating. Investors are watching ahead of Jan. 27, when UnitedHealth will report 2025 results and 2026 guidance. Scrutiny remains on medical-cost trends, operational review progress, and ongoing Justice Department investigations into Medicare Advantage billing.
5 January 2026
·····
Healthcare Stocks Today: Weekend Headlines, 2026 Themes, and What to Watch Before Monday’s Open

Healthcare Stocks Today: Weekend Headlines, 2026 Themes, and What to Watch Before Monday’s Open

U.S. equity markets are closed for the weekend. Healthcare stocks face new catalysts for Monday, including policy scrutiny after a Wall Street Journal report on Medicare drug waste tied to UnitedHealth, Humana, and CVS Health, and Johnson & Johnson halting a mid-stage eczema drug trial. The S&P 500 remains near 7,000 as investors rotate into sectors with moderate valuations.
28 December 2025
··
Shops Open on Christmas Day 2025 in the USA: Where You Can Still Buy Groceries, Medicine, and Last-Minute Essentials

Shops Open on Christmas Day 2025 in the USA: Where You Can Still Buy Groceries, Medicine, and Last-Minute Essentials

Most major U.S. retailers and supermarkets are closed on Christmas Day 2025, according to national reports. CVS, Walgreens, 7-Eleven, and Sheetz remain open, though hours vary by location and pharmacy counters may have reduced service. Some Safeway stores are open with adjusted hours. Shoppers are advised to check local hours before heading out.
25 December 2025
··
CVS Stock After the Bell (Dec. 24, 2025): CVS Health Dips in After‑Hours Holiday Trade—Key News, Forecasts, and What to Watch Before the Next Open

CVS Stock After the Bell (Dec. 24, 2025): CVS Health Dips in After‑Hours Holiday Trade—Key News, Forecasts, and What to Watch Before the Next Open

CVS Health closed at $79.12 on Dec. 24, up 1.38% in a holiday-shortened session with light volume. After-hours trading saw shares slip to $79.01. The stock remains below its 52-week high of $85.15. A new Philadelphia lawsuit named CVS Caremark in an insulin pricing case, and a False Claims Act dispute continues to hang over the company.
25 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
1 2 3

Stock Market Today

  • Euronext Reports 5.8% Rise in FX Trading Revenue in Q1 2026
    May 19, 2026, 12:33 PM EDT. Euronext, a European capital market infrastructure operator, reported a 5.8% year-on-year increase in foreign exchange (FX) trading revenue for the first quarter of 2026. The growth highlights steady demand in FX markets despite volatile economic conditions. Euronext published its quarterly results showing resilience in trading operations, underlying its role in the European financial ecosystem.

Latest articles

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

19 May 2026
Toronto, May 19, 2026, 12:05 (EDT) Constellation Software shares jumped on Tuesday, rising 9.5% to C$2,860.21 at 11:40 a.m. in Toronto, as investors bought back into one of Canada’s biggest software names while the broader S&P/TSX composite edged lower. Google Finance showed the stock opening at C$2,625.00 and touching C$2,880.35 intraday. (Google) The move matters because trading resumed after Monday’s Victoria Day closure, giving investors a fresh chance to react to last week’s earnings, analyst calls and the broader debate over whether artificial intelligence will weaken or help the company’s portfolio of niche software businesses. TMX said Canadian exchanges would
InMed Soars 100% on $290M Migraine Deal

InMed Soars 100% on $290M Migraine Deal

19 May 2026
InMed Pharmaceuticals shares jumped 108.6% to $1.42 after agreeing to merge with Mentari Therapeutics in an all-stock deal, shifting focus to migraine prevention. The combined company will operate as Mentari, backed by a $290 million private placement, with InMed shareholders owning about 1.51%. Nearly 69.6 million shares traded, and InMed’s market value reached $5.7 million.
Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

19 May 2026
Anthropic has hired Andrej Karpathy, a founding OpenAI member and former Tesla AI executive, to join its pre-training team. Karpathy will work under Nick Joseph and lead efforts to use Claude to speed pre-training research. He starts this week. Anthropic has also added Chris Rohlf, a cybersecurity specialist, to its frontier red team.

Popular

Figma shares test rebound as AI bet delivers

Figma shares test rebound as AI bet delivers

18 May 2026
Figma traded at $23.20 Monday afternoon, valuing the company at $12.1 billion. First-quarter revenue jumped 46% to $333.4 million, and the company raised its 2026 revenue forecast to up to $1.428 billion. Paid customers rose 54% to about 690,000. Figma posted a GAAP net loss of $142.4 million but reported $56.5 million in non-GAAP net income.
Go toTop